Cargando…
SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study
COVID-19 vaccination during pregnancy protects infants against symptomatic COVID-19. Vaccination of lactating mothers may offer additional protection, but our understanding of immune responses in breast milk is limited. We, therefore, performed a single-center prospective cohort study of lactating m...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675665/ https://www.ncbi.nlm.nih.gov/pubmed/38005975 http://dx.doi.org/10.3390/vaccines11111643 |
_version_ | 1785141118481989632 |
---|---|
author | Hsiao, Hui-Mien DiMaggio, Langdon S. Perez, Maria A. Chen, Xuemin Stephens, Kathleen Gibson, Theda Anderson, Evan J. Rostad, Christina A. |
author_facet | Hsiao, Hui-Mien DiMaggio, Langdon S. Perez, Maria A. Chen, Xuemin Stephens, Kathleen Gibson, Theda Anderson, Evan J. Rostad, Christina A. |
author_sort | Hsiao, Hui-Mien |
collection | PubMed |
description | COVID-19 vaccination during pregnancy protects infants against symptomatic COVID-19. Vaccination of lactating mothers may offer additional protection, but our understanding of immune responses in breast milk is limited. We, therefore, performed a single-center prospective cohort study of lactating mothers who received a COVID-19 mRNA primary vaccine series to evaluate the durability, breadth, and neutralizing capacity of the antibody responses in breast milk. Spike IgG- and IgA-binding antibodies of ancestral SARS-CoV-2 in serum and breast milk were quantified over 9 months using Meso Scale Discovery (MSD) V-PLEX assays, and ancestral titers were compared to four variants of concern (Alpha, Beta, Delta, Gamma) at a single time point. Neutralizing antibodies against ancestral SARS-CoV-2 and Omicron BA.4/5 were compared before and after vaccination using a pseudovirus-neutralization assay. Eleven lactating mothers received either Pfizer BNT162b2 (7/11) or Moderna mRNA-1273 (4/11) vaccine primary series. IgG and IgA titers increased in serum and breast milk following each dose, peaking 1–4 weeks after series completion. Titers remained significantly elevated for 7–9 months, except for in breast milk IgA which returned to baseline within 1 month. Furthermore, binding antibodies against all included variants were detected in breast milk collected 1–3 weeks after series completion. However, while vaccination induced a strong neutralizing response against ancestral SARS-CoV-2 in serum and more modest response in breast milk, it did not induce neutralizing antibodies against Omicron BA.4/5 in either specimen type. This study demonstrates that maternal COVID-19 mRNA vaccination may enhance immune protection for infants through breast milk via increased IgG- and IgA-binding-and-neutralizing antibodies; although, variant-specific boosters may be required to optimize immune protection. |
format | Online Article Text |
id | pubmed-10675665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106756652023-10-26 SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study Hsiao, Hui-Mien DiMaggio, Langdon S. Perez, Maria A. Chen, Xuemin Stephens, Kathleen Gibson, Theda Anderson, Evan J. Rostad, Christina A. Vaccines (Basel) Article COVID-19 vaccination during pregnancy protects infants against symptomatic COVID-19. Vaccination of lactating mothers may offer additional protection, but our understanding of immune responses in breast milk is limited. We, therefore, performed a single-center prospective cohort study of lactating mothers who received a COVID-19 mRNA primary vaccine series to evaluate the durability, breadth, and neutralizing capacity of the antibody responses in breast milk. Spike IgG- and IgA-binding antibodies of ancestral SARS-CoV-2 in serum and breast milk were quantified over 9 months using Meso Scale Discovery (MSD) V-PLEX assays, and ancestral titers were compared to four variants of concern (Alpha, Beta, Delta, Gamma) at a single time point. Neutralizing antibodies against ancestral SARS-CoV-2 and Omicron BA.4/5 were compared before and after vaccination using a pseudovirus-neutralization assay. Eleven lactating mothers received either Pfizer BNT162b2 (7/11) or Moderna mRNA-1273 (4/11) vaccine primary series. IgG and IgA titers increased in serum and breast milk following each dose, peaking 1–4 weeks after series completion. Titers remained significantly elevated for 7–9 months, except for in breast milk IgA which returned to baseline within 1 month. Furthermore, binding antibodies against all included variants were detected in breast milk collected 1–3 weeks after series completion. However, while vaccination induced a strong neutralizing response against ancestral SARS-CoV-2 in serum and more modest response in breast milk, it did not induce neutralizing antibodies against Omicron BA.4/5 in either specimen type. This study demonstrates that maternal COVID-19 mRNA vaccination may enhance immune protection for infants through breast milk via increased IgG- and IgA-binding-and-neutralizing antibodies; although, variant-specific boosters may be required to optimize immune protection. MDPI 2023-10-26 /pmc/articles/PMC10675665/ /pubmed/38005975 http://dx.doi.org/10.3390/vaccines11111643 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hsiao, Hui-Mien DiMaggio, Langdon S. Perez, Maria A. Chen, Xuemin Stephens, Kathleen Gibson, Theda Anderson, Evan J. Rostad, Christina A. SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title | SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title_full | SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title_fullStr | SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title_full_unstemmed | SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title_short | SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study |
title_sort | sars-cov-2 antibody profiles in maternal serum and breast milk following mrna covid-19 vaccination: a longitudinal prospective observational cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675665/ https://www.ncbi.nlm.nih.gov/pubmed/38005975 http://dx.doi.org/10.3390/vaccines11111643 |
work_keys_str_mv | AT hsiaohuimien sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT dimaggiolangdons sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT perezmariaa sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT chenxuemin sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT stephenskathleen sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT gibsontheda sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT andersonevanj sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy AT rostadchristinaa sarscov2antibodyprofilesinmaternalserumandbreastmilkfollowingmrnacovid19vaccinationalongitudinalprospectiveobservationalcohortstudy |